CBC Group

Hunan Yiyi Pharmaceutical Technology develops and operates an online platform for pharmaceutical products. It allows members to purchase various medicines. Hunan Yiyi Pharmaceutical Technology was founded in 2019 and is based in Jiangsu, China.

Axbio Inc. is a biotechnology company based in Shenzhen, China, focused on developing and manufacturing advanced technology for genetic sequencing and molecular diagnostics. Founded in 2016, Axbio produces a variety of genome extraction kits for different sample types, including stool, blood, saliva, and bacteria. The company's offerings also include sequencing and diagnostic systems, disposable biochips, and reagents. Axbio's innovative platform utilizes semiconductor nanotechnology and microfluidics, allowing for high-throughput sequencing and diagnostics. This technology supports a range of applications, from low-cost handheld devices for bedside diagnostics to fully automated laboratory instruments, facilitating services such as early cancer screening, rapid pathogen detection, and drug development. Currently, Axbio is operating in stealth mode as it continues to enhance its product offerings and industrial solutions.

InxMed is a clinical-stage biotechnology company dedicated to developing innovative cancer therapeutics aimed at improving treatment outcomes for patients. The company focuses on creating "Best-in-Disease Combination" medicines, leveraging a deep understanding of disease biology and pharmacology to address various forms of cancer, including pancreatic, ovarian, and gastric cancers. InxMed aims to provide healthcare professionals with more effective treatment options by building a robust translational platform that integrates advanced expertise and efficient execution capabilities in drug development.

ENSEM Therapeutics is a pioneering drug discovery and development company focused on creating innovative small-molecule precision medicines for oncology. Utilizing its proprietary Kinetic Ensemble platform, the company specializes in detecting and characterizing rare conformational states of drug targets, which are crucial for understanding oncogenic processes, regulatory mechanisms, and drug resistance. This approach not only provides new therapeutic opportunities but also allows drug developers to address high-value targets that are typically challenging to target. With potential applications extending beyond oncology to genetic disorders and other disease areas, ENSEM Therapeutics aims to transform the landscape of precision medicine.

Trevena, Inc., founded in 2007 and headquartered in Chesterbrook, Pennsylvania, is a biopharmaceutical company dedicated to the development of innovative medicines for central nervous system (CNS) disorders. The company specializes in creating G protein-coupled receptor (GPCR) biased ligands, which aim to improve upon existing therapies by enhancing efficacy and reducing adverse effects. Trevena's pipeline includes several product candidates: Oliceridine injection, a mu-opioid receptor ligand completed Phase III trials for acute pain management; TRV250, a delta-opioid receptor agonist in Phase I study for migraine treatment; TRV734, a small molecule MOR ligand in Phase I study for acute and chronic pain; TRV027, currently in phase 2 clinical testing for the treatment of acute heart failure; and TRV045, an S1P modulator for managing chronic pain. Trevena has also collaborated with Imperial College London to evaluate Trv027 in Covid-19 patients.

Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company based in Boston, Massachusetts, specializing in the development and commercialization of innovative therapies derived from novel tetracycline chemistry. The company’s lead product, NUZYRA, is a broad-spectrum antibiotic administered in both oral and intravenous forms, targeting adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Another significant product, SEYSARA, is designed for the treatment of moderate to severe acne vulgaris. Paratek has received Qualified Infectious Disease Product designation from the U.S. Food and Drug Administration for its lead antibiotic, reflecting its commitment to addressing urgent public health threats, including antibiotic resistance. The company maintains various collaboration agreements, including partnerships with Zai Lab and Allergan, as well as research agreements with academic institutions and military organizations, to further its mission in combating infectious diseases and exploring additional therapeutic areas such as multiple sclerosis and systemic inflammatory diseases.

ABio-X is a biotechnology holding company headquartered in Waltham, Massachusetts, dedicated to incubating organizations that merge innovative science with advanced technologies. Its primary focus is on developing transformative medicines and solutions aimed at addressing global health challenges. Each incubated company operates with its own product portfolio and leadership team while benefiting from a centralized shared services environment, which enhances operational efficiency and fosters innovation. Through this model, ABio-X aims to drive significant advancements in the biotechnology sector and improve patient outcomes worldwide.

Jadeite Medicines is a biopharmaceutical company dedicated to developing and commercializing innovative pharmaceutical products. The company aims to address unmet clinical needs by creating novel medicines that enhance treatment options for patients. Through its focus on research and development, Jadeite Medicines seeks to improve healthcare outcomes and advance the field of medicine.

NiKang Therapeutics, Inc. is a biotechnology company established in 2017 and headquartered in Wilmington, Delaware. The company specializes in the discovery and development of small molecule oncology medicines aimed at addressing unmet medical needs in cancer treatment. Utilizing a discovery approach informed by target structure biology, NiKang employs structure-based drug design to facilitate the rapid and efficient development of proprietary drug candidates. This methodology enables the company to create innovative therapies with desirable pharmacological properties, ultimately aimed at improving the lives of patients through enhanced treatment options.

Lu Daopei Medical Group, established in 2002 and headquartered in Beijing, China, operates a chain of hospitals specializing in hematology-related treatments. The group is renowned for its expertise in bone marrow transplantation, offering services such as the Department of BMT, Department of General Hematology, Lymphoma and Myeloma Center, and Pathology & Specialty Hematology Lab. Additionally, they provide stem cell transplantation, oncology care, clinical diagnosis, and support patients throughout their treatment journey to reduce anxiety.